vs
Side-by-side financial comparison of Republic Services (RSG) and Viatris (VTRS). Click either name above to swap in a different company.
Republic Services is the larger business by last-quarter revenue ($4.1B vs $3.7B, roughly 1.1× Viatris). On growth, Viatris posted the faster year-over-year revenue change (5.0% vs 2.2%). Viatris produced more free cash flow last quarter ($619.3M vs $404.0M). Over the past eight quarters, Republic Services's revenue compounded faster (3.5% CAGR vs 0.5%).
Republic Services, Inc. is a North American waste disposal company whose services include non-hazardous solid waste collection, waste transfer, waste disposal, recycling, and energy services. It is the second largest provider of waste disposal in the United States after Waste Management. Its operations primarily consist of providing collection, transfer, and disposal of non-hazardous solid waste, recovering and recycling of certain materials, and energy services. The company is 35.
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.
RSG vs VTRS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.1B | $3.7B |
| Net Profit | $544.7M | — |
| Gross Margin | 41.9% | 31.1% |
| Operating Margin | 19.4% | -5.2% |
| Net Margin | 13.2% | — |
| Revenue YoY | 2.2% | 5.0% |
| Net Profit YoY | 6.3% | — |
| EPS (diluted) | $1.76 | $-0.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.1B | $3.7B | ||
| Q3 25 | $4.2B | $3.7B | ||
| Q2 25 | $4.2B | $3.6B | ||
| Q1 25 | $4.0B | $3.2B | ||
| Q4 24 | $4.0B | $3.5B | ||
| Q3 24 | $4.1B | $3.7B | ||
| Q2 24 | $4.0B | $3.8B | ||
| Q1 24 | $3.9B | $3.7B |
| Q4 25 | $544.7M | — | ||
| Q3 25 | $549.7M | — | ||
| Q2 25 | $549.9M | — | ||
| Q1 25 | $495.0M | — | ||
| Q4 24 | $512.2M | — | ||
| Q3 24 | $565.7M | — | ||
| Q2 24 | $511.5M | — | ||
| Q1 24 | $453.8M | — |
| Q4 25 | 41.9% | 31.1% | ||
| Q3 25 | 41.5% | 36.6% | ||
| Q2 25 | 42.2% | 37.3% | ||
| Q1 25 | 42.3% | 35.8% | ||
| Q4 24 | 42.7% | 34.6% | ||
| Q3 24 | 41.9% | 39.0% | ||
| Q2 24 | 41.1% | 38.2% | ||
| Q1 24 | 40.9% | 41.2% |
| Q4 25 | 19.4% | -5.2% | ||
| Q3 25 | 19.8% | 4.8% | ||
| Q2 25 | 20.3% | 6.5% | ||
| Q1 25 | 20.1% | -88.9% | ||
| Q4 24 | 19.9% | -5.1% | ||
| Q3 24 | 20.8% | 6.0% | ||
| Q2 24 | 20.1% | -6.3% | ||
| Q1 24 | 19.0% | 5.6% |
| Q4 25 | 13.2% | — | ||
| Q3 25 | 13.1% | — | ||
| Q2 25 | 13.0% | — | ||
| Q1 25 | 12.3% | — | ||
| Q4 24 | 12.7% | — | ||
| Q3 24 | 13.9% | — | ||
| Q2 24 | 12.6% | — | ||
| Q1 24 | 11.8% | — |
| Q4 25 | $1.76 | $-0.34 | ||
| Q3 25 | $1.76 | $-0.11 | ||
| Q2 25 | $1.75 | $0.00 | ||
| Q1 25 | $1.58 | $-2.55 | ||
| Q4 24 | $1.63 | $-0.43 | ||
| Q3 24 | $1.80 | $0.08 | ||
| Q2 24 | $1.62 | $-0.27 | ||
| Q1 24 | $1.44 | $0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $76.0M | $1.3B |
| Total DebtLower is stronger | $13.0B | — |
| Stockholders' EquityBook value | $12.0B | $14.7B |
| Total Assets | $34.4B | $37.2B |
| Debt / EquityLower = less leverage | 1.08× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $76.0M | $1.3B | ||
| Q3 25 | $84.0M | $975.3M | ||
| Q2 25 | $122.0M | $566.4M | ||
| Q1 25 | $83.0M | $755.0M | ||
| Q4 24 | $74.0M | $734.8M | ||
| Q3 24 | $83.4M | $1.9B | ||
| Q2 24 | $490.6M | $917.2M | ||
| Q1 24 | $91.6M | $1.0B |
| Q4 25 | $13.0B | — | ||
| Q3 25 | $12.4B | — | ||
| Q2 25 | $12.5B | — | ||
| Q1 25 | $12.9B | — | ||
| Q4 24 | $11.9B | — | ||
| Q3 24 | $12.0B | — | ||
| Q2 24 | $11.5B | — | ||
| Q1 24 | $11.4B | — |
| Q4 25 | $12.0B | $14.7B | ||
| Q3 25 | $11.9B | $15.2B | ||
| Q2 25 | $12.1B | $15.6B | ||
| Q1 25 | $11.7B | $15.7B | ||
| Q4 24 | $11.4B | $18.6B | ||
| Q3 24 | $11.2B | $19.8B | ||
| Q2 24 | $11.0B | $19.5B | ||
| Q1 24 | $10.8B | $20.0B |
| Q4 25 | $34.4B | $37.2B | ||
| Q3 25 | $33.8B | $37.9B | ||
| Q2 25 | $33.4B | $38.4B | ||
| Q1 25 | $33.1B | $38.5B | ||
| Q4 24 | $32.4B | $41.5B | ||
| Q3 24 | $31.8B | $44.8B | ||
| Q2 24 | $31.9B | $45.3B | ||
| Q1 24 | $31.4B | $47.3B |
| Q4 25 | 1.08× | — | ||
| Q3 25 | 1.04× | — | ||
| Q2 25 | 1.04× | — | ||
| Q1 25 | 1.10× | — | ||
| Q4 24 | 1.04× | — | ||
| Q3 24 | 1.07× | — | ||
| Q2 24 | 1.05× | — | ||
| Q1 24 | 1.05× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $981.0M | $815.8M |
| Free Cash FlowOCF − Capex | $404.0M | $619.3M |
| FCF MarginFCF / Revenue | 9.8% | 16.8% |
| Capex IntensityCapex / Revenue | 14.0% | 5.3% |
| Cash ConversionOCF / Net Profit | 1.80× | — |
| TTM Free Cash FlowTrailing 4 quarters | $2.4B | $1.9B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $981.0M | $815.8M | ||
| Q3 25 | $1.2B | $744.9M | ||
| Q2 25 | $1.1B | $219.7M | ||
| Q1 25 | $1.0B | $535.5M | ||
| Q4 24 | $1.0B | $482.7M | ||
| Q3 24 | $1.0B | $826.5M | ||
| Q2 24 | $1.1B | $379.1M | ||
| Q1 24 | $811.5M | $614.6M |
| Q4 25 | $404.0M | $619.3M | ||
| Q3 25 | $737.0M | $658.1M | ||
| Q2 25 | $702.0M | $166.8M | ||
| Q1 25 | $566.0M | $492.9M | ||
| Q4 24 | $524.4M | $342.3M | ||
| Q3 24 | $563.6M | $749.5M | ||
| Q2 24 | $696.0M | $320.3M | ||
| Q1 24 | $297.0M | $564.8M |
| Q4 25 | 9.8% | 16.8% | ||
| Q3 25 | 17.5% | 17.6% | ||
| Q2 25 | 16.6% | 4.7% | ||
| Q1 25 | 14.1% | 15.2% | ||
| Q4 24 | 13.0% | 9.7% | ||
| Q3 24 | 13.8% | 20.1% | ||
| Q2 24 | 17.2% | 8.5% | ||
| Q1 24 | 7.7% | 15.5% |
| Q4 25 | 14.0% | 5.3% | ||
| Q3 25 | 10.5% | 2.3% | ||
| Q2 25 | 9.6% | 1.5% | ||
| Q1 25 | 11.4% | 1.3% | ||
| Q4 24 | 12.3% | 4.0% | ||
| Q3 24 | 10.8% | 2.1% | ||
| Q2 24 | 10.0% | 1.6% | ||
| Q1 24 | 13.3% | 1.4% |
| Q4 25 | 1.80× | — | ||
| Q3 25 | 2.15× | — | ||
| Q2 25 | 2.02× | — | ||
| Q1 25 | 2.07× | — | ||
| Q4 24 | 2.00× | — | ||
| Q3 24 | 1.77× | — | ||
| Q2 24 | 2.15× | — | ||
| Q1 24 | 1.79× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RSG
| Other | $1.1B | 26% |
| Landfill Service Line | $780.0M | 19% |
| Collection Service Line Residential | $761.0M | 18% |
| Transfer Service Line | $458.0M | 11% |
| Environmental Solutions Service Line | $435.0M | 11% |
| Group3Segment | $423.0M | 10% |
| Other Service Line Sale Of Recycled Commodities | $104.0M | 3% |
| Other Service Line Other Noncore | $94.0M | 2% |
| Collection Service Line Other | $18.0M | 0% |
VTRS
| Brands | $1.2B | 32% |
| Generics | $1.1B | 29% |
| Lipitor | $377.3M | 10% |
| Norvasc | $175.2M | 5% |
| Other | $136.6M | 4% |
| Lyrica | $119.8M | 3% |
| Viagra | $104.2M | 3% |
| Creon | $98.9M | 3% |
| Epi Pen Auto Injectors | $79.0M | 2% |
| Yupelri | $70.6M | 2% |
| Effexor | $68.1M | 2% |
| Zoloft | $66.8M | 2% |
| Celebrex | $66.2M | 2% |
| Xalabrands | $42.0M | 1% |
| Dymista | $38.6M | 1% |
